Study of Etanercept for the Prevention of Complications Resulting From Hematopoietic Stem Cell Transplantation (HSCT)
Status:
Completed
Trial end date:
2012-09-01
Target enrollment:
Participant gender:
Summary
This is a clinical trial to see if the addition of etanercept to standard preventative
medicines helps in preventing two major complications of hematopoietic stem cell
transplantation (HSCT): decrease the rate of acute graft-vs-host disease (GVHD) and the risk
of death.
Phase:
Phase 2
Details
Lead Sponsor:
University of Michigan Cancer Center University of Michigan Rogel Cancer Center